Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8713163 | Journal of Allergy and Clinical Immunology | 2018 | 38 Pages |
Abstract
TENOR II provides longitudinal data to characterize disease progression, heterogeneity, and severity in patients with severe or difficult-to-treat asthma. Findings show continued morbidity, including a high degree of comorbid conditions, allergic sensitization, exacerbations, and very poorly controlled asthma, including reduced lung function.
Keywords
mini Asthma Quality of Life QuestionnaireATAQFVCNHLBIGERDATSFeNOAsthmaAmerican Thoracic SocietyThe Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimensemergency departmentgastroesophageal reflux diseaseExacerbationsFollow-uptenorFraction of exhaled nitric oxideSevereLong-termforced vital capacityNational Heart, Lung, and Blood InstituteObservational studypatient-reported outcomePROAsthma Therapy Assessment QuestionnaireControl
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Bradley E. MD, Tmirah PhD, Brandee PharmD, Benjamin MD, Eugene R. MD, Farid PhD, Aimee J. MA, Stanley J. MD, Robert S. MD, PhD,